How Much Does Matter ESG Ratings in Big Pharma Firms Performances?

Sophia Veronica Barbieri () and Laura Pellegrini ()
Additional contact information
Laura Pellegrini: University of Bari “Aldo Moro”

Chapter Chapter 9 in Climate Change Adaptation, Governance and New Issues of Value, 2022, pp 185-225 from Palgrave Macmillan

Abstract: Abstract Given the peculiarities of the pharmaceutical sector and its wide exposure to ESG factors, this chapter aims to verify the possible presence and the strength of a relationship between firms ESG scores and their economic-financial performance. We consider a benchmark sample of 103 pharmaceutical companies listed around the world, exhibiting ESG scores from 2004 to 2018. Firstly, results showed that the governance score has a negative impact on ROA and a positive impact on Tobin's Q. Secondly, considering the firm size, all the ESG scores on which research hypotheses were tested gain statistical significance. In particular, for smaller pharmaceutical companies, both the governance and controversies score have a negative impact on ROA. While, as the firm size grows, the controversies score has a positive impact on both ROA and Tobin's Q. Finally, there is an inverted U-shaped non-linear relationship between ESG scores and Tobin’s Q.

Date: 2022
References: Add references at CitEc
Citations:

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:pal:psifcp:978-3-030-90115-8_9

Ordering information: This item can be ordered from
http://www.palgrave.com/9783030901158

DOI: 10.1007/978-3-030-90115-8_9

Access Statistics for this chapter

More chapters in Palgrave Studies in Impact Finance from Palgrave Macmillan
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().